Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins
| Autor: | Ricardo J. Gonzalez, Cruse Cw, Matthew C. Perez, William J. Fulp, Jane L. Messina, Jonathan S. Zager, Young-Chul Kim, Amod A. Sarnaik, Vernon K. Sondak, Evan S. Weitman, Daniel Lee |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Microstaging
medicine.medical_specialty Surgical margin Sentinel lymph node Melanoma in situ Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences melanoma in situ 0302 clinical medicine Biopsy medicine melanoma Sampling (medicine) Case Series Breslow depth sentinel lymph node biopsy medicine.diagnostic_test business.industry Melanoma medicine.disease surgical margin Oncology 030220 oncology & carcinogenesis Re biopsy atypical melanocytic proliferation Radiology business |
| Zdroj: | Melanoma Management |
| ISSN: | 2045-0893 2045-0885 |
| Popis: | Aim: To assess the impact of re-biopsy on partially sampled melanoma in situ (MIS), atypical melanocytic proliferation (AMP) and thin invasive melanoma. Materials & methods: We retrospectively identified cases of re-biopsied partially sampled neoplasms initially diagnosed as melanoma in situ, AMP or thin melanoma (Breslow depth ≤0.75 mm). Results & conclusion: Re-biopsy led to sentinel lymph node biopsy (SLNB) in 18.3% of cases. No patients upstaged from AMP or MIS had a positive SLNB. One out of nine (11.1%) initially diagnosed as a thin melanoma ≤0.75 mm, upstaged with a re-biopsy, had a positive SLNB. After re-biopsy 8.5% underwent an increased surgical margin. Selective re-biopsy of partially sampled melanoma with gross residual disease can increase the accuracy of microstaging and optimize treatment regarding surgical margins and SLNB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|